Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine
California
92618
United States
Tel: 949-788-6700
Fax: 949-788-6706
Website: http://www.spectrumpharm.com/
Email: info@spectrumpharm.com
616 articles about Spectrum Pharmaceuticals, Inc.
-
Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer
9/5/2018
The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial
-
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September 2018
8/30/2018
Spectrum Pharmaceuticals, Inc. today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th.
-
Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update
8/9/2018
An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto
-
Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast
8/2/2018
Spectrum Pharmaceuticals announced it will host a teleconference and webcast with management to discuss the second quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 9, 2018 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
6/29/2018
ADVANCE, first Phase 3 study, met the non-inferiority of ROLONTIS to pegfilgrastim endpoint in the Duration of Severe Neutropenia (DSN) across all 4 cycles (all p<0.0001)
-
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
-
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th
5/30/2018
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference.
-
CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results
5/15/2018
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), today reported financial results for the first quarter and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update
5/3/2018
Spectrum Pharmaceuticals, Inc. announced financial results for the three-month period ended March 31, 2018.
-
Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
5/3/2018
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib.
-
Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes
4/30/2018
Spectrum Pharmaceuticals, Inc. announced that it has taken a number of actions designed to further enhance its corporate governance practices.
-
Company Profile for SPECTRUM PHARMACEUTICALS
4/27/2018
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
-
Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
4/10/2018
Spectrum Pharmaceuticals, Inc.announced that updated poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant Non-Small Cell Lung Cancer study are available, based on longer follow-up.
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update
3/6/2018
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period and year ended December 31, 2017.
-
Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors
2/27/2018
The appointment will increase the size of the Board of Directors to nine members
-
Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd
2/15/2018
The Company presentation is on Thursday, February 22, 2018, at 10:30 AM ET.
-
Spectrum Pharma fired CEO Rajesh C. Shrotriya without cause, the company announced late Sunday.
-
Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)
12/13/2017
In the 29 patients evaluable for response, the investigator assessed objective response (OR) and complete response (CR) rates were 90% and 66%, respectively.
-
Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017
12/4/2017
Spectrum Pharmaceuticals announced key presentations of clinical and scientific data related to its products at the 59th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 9-12, 2017.
-
Investors have had a decent year, but some have much to be grateful for this Thanksgiving.